...
首页> 外文期刊>Journal of Oral and Maxillofacial Surgery >Comorbidity Assessment in Patients With Oral Squamous Cell Carcinoma: Can Imaging Techniques (Fludeoxyglucose Positron-Emission Tomographic Computed Tomography and Contrast-Enhanced Computed tomography) Provide Additional Information?
【24h】

Comorbidity Assessment in Patients With Oral Squamous Cell Carcinoma: Can Imaging Techniques (Fludeoxyglucose Positron-Emission Tomographic Computed Tomography and Contrast-Enhanced Computed tomography) Provide Additional Information?

机译:口腔鳞状细胞癌患者的合并症评估:CAN成像技术(Fludexyglucose正电子 - 发射断层摄影层析术和对比增强的计算机断层扫描)提供了额外的信息吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose This study evaluated the role of imaging staging examinations (positron-emission tomographic computed tomography [PET/CT] and contrast-enhanced computed tomography [ceCT]) for the assessment of the comorbidity status of patients with oral squamous cell carcinoma (OSCC). A binary null hypothesis was drafted: 1) imaging staging examinations do not augment knowledge about the comorbidity status of patients with OSCC and 2) there is no difference between PET/CT and ceCT in this regard. Materials and Methods A retrospective cohort study design was selected to address the research question. Patients with histologically confirmed OSCC who underwent whole-body staging by PET/CT or ceCT from 2012 through 2015 were considered for inclusion according to predefined criteria. Data collection was performed by the review of patient charts and histology, radiology, and nuclear medicine reports. The Charlson Comorbidity Index (CCI) was chosen to quantify comorbidity and was calculated before and after staging and then compared. The type of imaging staging examination (PET/CT or ceCT) served as the predictor variable and the CCI was determined as the primary outcome variable. Descriptive and inferential statistics were computed for the variable scale. The significance level was set at a P value less than or equal to .05. Results The sample was composed of 178 patients (71 women, 107 men; average age, 64.2爕r) of whom 109 (61%) underwent PET/CT and 69 (39%) underwent ceCT staging. The pre- and post-staging CCI notably differed. Neither imaging technique showed superior results. Conclusion Relevant and otherwise covert comorbidities can be found by the performance of imaging staging examinations. This enables clinicians to better assess the peri-therapeutic risk and prognosis of patients with OSCC. Therefore, a detailed evaluation of incidental findings on imaging studies is warranted and recommended.
机译:目的本研究评估了成像分期检查的作用(正电子 - 排放断层扫描断层扫描[PET / CT]和对比增强的计算断层扫描[CECT]),用于评估口腔鳞状细胞癌(OSCC)的患者的合并症状态。起草二进制无效假设:1)成像分期考试不会增加关于OSCC患者的合并状态的知识和2)PET / CT和CECT之间没有区别。材料和方法选择了回顾性队列研究设计,以解决研究问题。通过预定标准考虑由PET / CT或CECT接受全身分期的组织学证实的OSCC的患者被认为是纳入的预定标准。通过审查患者图表和组织学,放射学和核医学报告进行数据收集。选择查理合并症指数(CCI)以量化合并症,并在分段之前和之后计算。作为预测器变量和CCI的成像分期检查(PET / CT或CEct)的类型被确定为主要结果变量。对变量刻度计算描述性和推理统计。显着水平设定为小于或等于.05的P值。结果样品由178名患者组成(71名女性,107名男性;平均年龄,64.2爕r),其中109(61%)接受了PET / CT和69(39%)接受了CECT分期。预期和后期CCI明显不同。两种成像技术都没有显示出优异的结果。结论相关且否则隐蔽的合并症可以通过成像分期考试的性能找到。这使得临床医生能够更好地评估OSCC患者的Peri治疗风险和预后。因此,有保证和建议对成像研究进行附带发现的详细评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号